Abstract
Rubitecan (RFS-2000, 9NC, Orathecin) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-fluorouracil based chemotherapy. Fourteen eligible patients were treated with rubitecan at 1.5 mg/m2/day on a 5 day/week continuous schedule. Therapy was well tolerated with most adverse events in the mild to moderate category. Grade 3/4 toxicity consisting of anemia, diarrhea and elevated bilirubin was seen in 4 patients. No responses were seen in 13 evaluable patients. Overall median survival (95% confidence interval) was 10.1 (range 3.1-12.6) months, and median time to progression was 2.1 months. Administration of rubitecan was well tolerated, but this schedule does not appear to have clinical activity in patients with advanced previously treated CRC.
References
Jan 1, 1990·Advances in Pharmacology·E SchneiderL F Liu
Nov 24, 1989·Science·B C GiovanellaM Potmesil
Mar 1, 1989·Controlled Clinical Trials·R Simon
Aug 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PazdurR Winn
Nov 14, 1997·Cancer·L B SaltzD P Kelsen
Dec 10, 1997·American Journal of Clinical Oncology·R PazdurJ Ajani
Mar 10, 1998·Anti-cancer Drugs·C F VerschraegenJ S Stehlin
Nov 10, 1998·Lancet·D CunninghamP Herait
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L DrenglerM L Rothenberg
May 13, 1999·Cancer Chemotherapy and Pharmacology·W C ZamboniC F Stewart
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Feb 24, 2001·Annals of the New York Academy of Sciences·R J BernackiW R Greco
Apr 9, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P SchöffskiJ Wanders
Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P RougierD Méry-Mignard
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mace L RothenbergDaniel G Haller
Jul 5, 2003·Lancet·Joseph F Pizzolato, Leonard B Saltz
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
May 4, 2004·Investigational New Drugs·Hedy L KindlerEverett E Vokes
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William C ZamboniRamesh K Ramanathan
Aug 24, 2004·Cancer Chemotherapy and Pharmacology·Laura L JungWilliam C Zamboni
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Citations
Sep 21, 2007·Cancer Chemotherapy and Pharmacology·Francesco CaponigroPatricia Pollard
Dec 4, 2013·Future Oncology·Raj Kumar Shukla
Jan 9, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jian ZhengFanfan Zhou
Sep 11, 2012·Drug Discovery Today·Silvia MazzaferroGilles Ponchel
Sep 9, 2016·ELife·Romi GuptaNarendra Wajapeyee